Unknown

Dataset Information

0

Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.


ABSTRACT: The development of targeted therapies and the resurgence of immunotherapy offer enormous potential to dramatically improve the outlook for patients with invasive urothelial carcinoma (InvUC). Optimization of these therapies, however, is crucial as only a minority of patients achieve dramatic remission, and toxicities are common. With the complexities of the therapies, and the growing list of possible drug combinations to test, highly relevant animal models are needed to assess and select the most promising approaches to carry forward into human trials. The animal model(s) should possess key features that dictate success or failure of cancer drugs in humans including tumor heterogeneity, genetic-epigenetic crosstalk, immune cell responsiveness, invasive and metastatic behavior, and molecular subtypes (e.g., luminal, basal). While it may not be possible to create these collective features in experimental models, these features are present in naturally-occurring InvUC in pet dogs. Naturally occurring canine InvUC closely mimics muscle-invasive bladder cancer in humans in regards to cellular and molecular features, molecular subtypes, biological behavior (sites and frequency of metastasis), and response to therapy. Clinical treatment trials in pet dogs with InvUC are considered a win-win scenario; the individual dog benefits from effective treatment, the results are expected to help other dogs, and the findings are expected to translate to better treatment outcomes in humans. This review will provide an overview of canine InvUC, the similarities to the human condition, and the potential for dogs with InvUC to serve as a model to predict the outcomes of targeted therapy and immunotherapy in humans.

SUBMITTER: Sommer BC 

PROVIDER: S-EPMC5929349 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.

Sommer Breann C BC   Dhawan Deepika D   Ratliff Timothy L TL   Knapp Deborah W DW  

Bladder cancer (Amsterdam, Netherlands) 20180426 2


The development of targeted therapies and the resurgence of immunotherapy offer enormous potential to dramatically improve the outlook for patients with invasive urothelial carcinoma (InvUC). Optimization of these therapies, however, is crucial as only a minority of patients achieve dramatic remission, and toxicities are common. With the complexities of the therapies, and the growing list of possible drug combinations to test, highly relevant animal models are needed to assess and select the mos  ...[more]

Similar Datasets

| S-EPMC6101404 | biostudies-literature
2018-08-01 | GSE110661 | GEO
| S-EPMC6046303 | biostudies-literature
| S-EPMC4569341 | biostudies-literature
| S-EPMC5897971 | biostudies-literature
| S-EPMC7198768 | biostudies-literature
| S-EPMC2929888 | biostudies-literature
| S-EPMC5805257 | biostudies-literature
| PRJNA434265 | ENA
| S-EPMC4340376 | biostudies-literature